Abstract:Vascular smooth muscle cell (VSMC) phenotype switching is a pathological hallmark in various cardiovascular diseases. N4-acetylcytidine (ac4C) catalyzed by N-acetyltransferase 10 (NAT10) is well conserved in the enzymatic modification of ribonucleic acid (RNA). NAT10-mediated ac4C acetylation is involved in various physiological and pathological processes, including cardiac remodelling. However, the biological functions and underlying regulatory mechanisms of mRNA ac4C modifications in vascular diseases remain elusive. By combining in-vitro and in-vivo vascular injury models, NAT10 was identified as a crucial protein involved in the promotion of post-injury neointima formation, as well as VSMC phenotype switching. The potential mechanisms of NAT10 in the vascular neointima formation were clarified by RNA sequence (RNA-seq), acetylated mRNA immunoprecipitation sequence (acRIP-seq), and RNA binding protein immunoprecipitation sequence (RIP-seq). NAT10 and ac4C modifications were upregulated in injured human and rodent arteries. Deletion of NAT10 in VSMCs effectively reduced post-injury neointima formation and VSMC phenotype switching. Further RNA-seq, RIP-seq, and acRIP-seq revealed that NAT10, by its ac4C modification, directly interacts with genes, including integrin-β1 (ITGB1) and collagen type I alpha 2 chain (Col1a2) mRNAs. Taking ITGB1 as one example, it showed that NAT10-mediated ac4C consequently increased ITGB1 mRNA stability and its downstream focal adhesion kinase (FAK) signaling, directly influencing the proliferation of VSMCs and vascular remodelling. The regulation of NAT10 on the VSMC phenotype is of translational significance because the administration of Remodelin, a NAT10 inhibitor, effectively prevents neointima formation by suppressing VSMC proliferation and downregulating ITGB1 expression and deactivating its FAK signaling. This study reveals that NAT10 promotes vascular remodelling via mRNA ac4C acetylation, which may be a promising therapeutic target against vascular remodelling. N-acetyltransferase 10 (NAT10)-mediated N4-acetylcytidine (ac4C) mRNA acetylation regulates vascular smooth muscle cell (VSMC) phenotype switching and vascular remodelling. Stress, such as injury, upregulates NAT10, which directly interacts with downstream target genes, including integrin-β1 (ITGB1) mRNA. NAT10-mediated ac4C mRNA acetylation subsequently increases ITGB1 mRNA stability and downstream focal adhesion kinase (FAK) signaling, thereby inducing the phenotype switching of VSMCs, leading to vascular remodelling. Remodelin is a NAT10 acetyltransferase inhibitor. AKT, serine–threonine protein kinase; Col1a2, collagen type I alpha 2 chain; ERK, extracellular signal-regulated kinase; FAK, focal adhesion kinase; PDGF, platelet-derived growth factor; SRC, steroid receptor coactivator.

NAT10‐mediated RNA ac4C acetylation contributes to the myocardial infarction‐induced cardiac fibrosis

NAT10 Is Involved in Cardiac Remodeling Through ac4C-Mediated Transcriptomic Regulation

Acetylcytidine modification of Amotl1 by N-acetyltransferase 10 contributes to cardiac fibrotic expansion in mice after myocardial infarction

NAT10 promotes vascular remodelling via mRNA ac4C acetylation

tRNA-derived small RNA (tsr007330) regulates myocardial fibrosis after myocardial infarction through NAT10-mediated ac4C acetylation of EGR3 mRNA

NAT10 accelerates pulmonary fibrosis through N4-acetylated TGFB1-initiated epithelial-to-mesenchymal transition upon ambient fine particulate matter exposure

Loss of NAT10 Reduces the Translation of Kmt5a mRNA Through ac4C Modification in Cardiomyocytes and Induces Heart Failure

NAT10 promotes osteoclastogenesis in inflammatory bone loss by catalyzing Fos mRNA ac4C modification and upregulating MAPK signaling pathway

The mechanism of myocardial fibrosis is ameliorated by myocardial infarction-associated transcript through the PI3K/Akt signaling pathway to relieve heart failure

Inhibition of the Cardiac Fibroblast-Enriched Histone Methyltransferase Dot1L Prevents Cardiac Fibrosis and Cardiac Dysfunction

PIWI‐Interacting RNA HAAPIR Regulates Cardiomyocyte Death After Myocardial Infarction by Promoting NAT10‐Mediated ac 4 C Acetylation of Tfec mRNA

Downregulation of B4GALT5 Attenuates Cardiac Fibrosis Through Lumican and Akt/GSK-313/13-catenin Pathway

264The long noncoding RNA H19 modulates cardiac remodeling after infarction

Abstract 370: MicroRNA-19b Contributes to Cardiac Fibrosis

Downregulation of B4GALT5 attenuates cardiac fibrosis through Lumican and Akt/GSK-3β/β-catenin pathway

Modulation of Mir-10A-mediated TGF-β1/Smads Signaling Affects Atrial Fibrillation-Induced Cardiac Fibrosis and Cardiac Fibroblast Proliferation.

Polypyrimidine tract binding protein 1 exacerbates cardiac fibrosis by regulating fatty acid‐binding protein 5

N-Acetyltransferase 10 represses Uqcr11 and Uqcrb independently of ac4C modification to promote heart regeneration

Targeted inhibition of Focal Adhesion Kinase Attenuates Cardiac Fibrosis and Preserves Heart Function in Adverse Cardiac Remodeling

MIAT Is a Pro-fibrotic Long Non-coding RNA Governing Cardiac Fibrosis in Post-infarct Myocardium